Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
Lise J Estcourt, Claudia S. Cohn, Monica B. Pagano, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 9, pp. 1310-1321
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 125
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 83
Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K. Hayden, Ibrahim K El Mikati, Kimberly E. Hanson, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 60
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 37
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
Akshita Gupta, Angelina Konnova, Mathias Smet, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 30
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
Karine Lacombe, Thomas Hueso, Raphaël Porcher, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000427-e000427
Open Access | Times Cited: 16
Early antibody treatment, inflammation, and risk of post-COVID conditions
Kelly A. Gebo, Sonya L. Heath, Yuriko Fukuta, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 15
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 6
SARS‐CoV‐2 IgG antibodies in COVID‐19 convalescent plasma and conventional plasma units
Andrew Sulaiman, Isabella Sengsouk, Jodie L. White, et al.
Transfusion (2025)
Closed Access
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
Juan G. Ripoll, Ellen K. Gorman, Justin E. Juskewitch, et al.
Blood Advances (2022) Vol. 6, Iss. 23, pp. 5951-5955
Open Access | Times Cited: 24
Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
Scott A. McConnell, Jaiprasath Sachithanandham, Nathan J. Mudrak, et al.
Cell chemical biology (2023) Vol. 30, Iss. 7, pp. 726-738.e4
Open Access | Times Cited: 12
The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox
Evan M. Bloch, David J. Sullivan, Shmuel Shoham, et al.
mBio (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 19
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
Alina Seidel, Simone Hoffmann, Bernd Jahrsdörfer, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 9
Effect and safety of mesenchymal stem cells for patients with COVID‐19: Systematic review and meta‐analysis with trial sequential analysis
Zhijing Zhang, Shuai Shao, Xuefeng Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Open Access | Times Cited: 7
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19
Tayler A. Van Denakker, Arwa Z. Al‐Riyami, Rita Feghali, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 7, pp. 501-514
Closed Access | Times Cited: 7
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far
Hubert Schrezenmeier, Simone Hoffmann, Henrike Hofmann, et al.
Hämostaseologie (2023) Vol. 43, Iss. 01, pp. 067-074
Open Access | Times Cited: 5
COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients
Cameron Y. S. Lee, Jon B. Suzuki
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2055-2055
Open Access | Times Cited: 5
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
Feben Habtehyimer, Xianming Zhu, Andrew D. Redd, et al.
Microbiology Spectrum (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Convalescent Plasma for Immunocompromised Patients
Shmuel Shoham
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
Maxime Desmarets, Simone Hoffmann, Charline Vauchy, et al.
BMJ Open (2023) Vol. 13, Iss. 4, pp. e071277-e071277
Open Access | Times Cited: 4
Exercise and Experiments of Nature
Michael J. Joyner, Chad C. Wiggins, Sarah E. Baker, et al.
Comprehensive physiology (2023), pp. 4879-4907
Closed Access | Times Cited: 4
COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trial
Karine Lacombe, Thomas Hueso, Raphaël Porcher, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top